A study led by the School of Engineering of the Hong Kong University of Science and Technology (HKUST) has developed an innovative method that overcomes the limitations of traditional additive ...

Additive manufacturing of cellular lattice structures has emerged as a transformative approach to fabricating lightweight, high-performance materials with precise control over internal architecture.

CAMBRIDGE, England & STEVENAGE, England--(BUSINESS WIRE)--Cellular Origins, a TTP Company focused on enabling scalable, cost-effective, and efficient manufacture of cell and gene therapies (CGTs), and ...

Chimeric antigen receptor (CAR) T-cell therapy has revolutionized treatment for non-responsive or relapsing hematological malignancies, providing an intensive, personalized form of immunotherapy. It ...

Cellular Origins, a TTP Company focused on enabling scalable, cost-effective, and efficient manufacture of cell and gene therapies (CGTs), has today announced a collaborative partnership with ...

Cellular Origins, a TTP company, acquired the ACTIA (Autologous Cell Therapy Industrial Automation) Platform IP, developed by Geoff Hodge while CEO of SOTIO Biotech US. The ACTIA Platform complements ...